TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28887113
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg TCZ
Study: 28887113
Drug: 8 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/kg TCZ
Study: 12849880
Drug: Both antiepileptic
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both antiepileptic drugs
Study: 9226732
Drug: 2 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/70 kg butorphanol, IV, in ice-cold water (2 degrees C)
Study: 9226732
Drug: 10 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/70 kg morphine, IV, in ice-cold water (2 degrees C)
Study: 9226732
Drug: 10 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/70 kg morphine, IV, in warm water (37 degrees C)
Study: 9226732
Drug: 2 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/70 kg butorphanol, IV, in warm water (37 degrees C)
Study: 11532487
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (control)
Study: 22873117
Drug: l-NAME (NO
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-NAME (NO synthase inhibitor)
Study: 16859516
Drug: Operant Behavioural
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Operant Behavioural Treatment (OBT)
Study: 25031289
Drug: Gentamicin 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 240 mg intramuscularly plus Azithromycin 2 g orally
Study: 25031289
Drug: Gemifloxacin 320
Normalized name: gemifloxacin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin 320 mg orally plus Azithromycin 2 g orally
Study: 8678278
Drug: Alcuronium 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcuronium 0.25 mg/kg with thiopentone 7 mg/kg i.v. (Group A)
Study: 8678278
Drug: Atracurium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.5 mg/kg with thiopentone 7 mg/kg i.v. (Group C)
Study: 8678278
Drug: Alcuronium 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcuronium 0.25 mg/kg with propofol TIVA (Group B)
Study: 8678278
Drug: Atracurium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.5 mg/kg with propofol TIVA (Group D)
Study: 8678278
Drug: Atracurium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.5 mg/kg with thiopentone (Group E)
Study: 8678278
Drug: Propofol 1%
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 1% 3 mg/kg given at the beginning of recovery phase
Study: 1359745
Drug: Zileuton 800
Normalized name: Zileuton
DrugBank: Zileuton (DB00744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zileuton 800 mg b.i.d.
Study: 2870809
Drug: Ciclopirox olamine
Normalized name: Ciclopirox Olamine
DrugBank: Ciclopirox (DB01188)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclopirox olamine 1% applied twice daily for 28 days
Study: 29336265
Drug: Topical Plantavera
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Plantavera gel
Study: 29336265
Drug: Topical Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Placebo gel
Study: 24655487
Drug: Oily fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oily fish (salmon) providing 274 mg EPA + 671 mg DHA per day
Study: 24655487
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplement providing 396 mg EPA + 250 mg DHA per day
Study: 8598549
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplement
Study: 20451454
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine (18 g/m²)
Study: 20451454
Drug: Low-dose cytarabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytarabine (2 g/m²)
Study: 12586512
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg 'Fast' formulation (12 h)
Study: 12586512
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg 'Slow' formulation (24 h)
Study: 12586512
Drug: 2x15 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x15 mg immediate release tablets (12 h interval)
Study: 10669909
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of rifampicin and isoniazid
Study: 10669909
Drug: Separate formulations
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate formulations of rifampicin and isoniazid
Study: 8915147
Drug: Combination patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination patch testing (two different sets of five patches each containing combinations of three or four allergens per patch)
Study: 8915147
Drug: Conventional patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional patch testing (17 standard allergens applied individually)
Study: 8915147
Drug: Combination patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination patch testing (combination patches 1 and 2)
Study: 8915147
Drug: Conventional patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional patch testing
Study: 8915147
Drug: Combination patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination patch testing
Study: 1855691
Drug: Combination tablet
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tablet of cimetidine 200 mg and alginic acid 500 mg, taken one tablet four times daily (increased to two tablets four times daily if response was unsatisfactory after six weeks)
Study: 1855691
Drug: Standard dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosage of cimetidine 400 mg four times daily
Study: 1855691
Drug: Combination tablet
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tablet of cimetidine 200 mg and alginic acid 500 mg
Study: 29544551
Drug: Cognitive Remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Remediation Therapy (CRT) - intensive, group, and independent methods
Study: 25307535
Drug: Achieved LDL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Achieved LDL target (< 2.0 mmol/L)
Study: 18022000
Drug: Intravenous N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous N-acetylcysteine (NAC) 300 mg along with hydration (500 mL multielectrolyte fluid)
Study: 18022000
Drug: Hydration (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration (500 mL multielectrolyte fluid) only
Study: 16146256
Drug: 0.05 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mL/kg nebulized L-epinephrine
Study: 16146256
Drug: 0.5 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL/kg nebulized L-epinephrine
Study: 12163671
Drug: Oral tracer
Normalized name: Tracleer Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tracer protocol
Study: 12163671
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) tracer protocol
Study: 10485962
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg oral)
Study: 24245707
Drug: Internet-based exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based exposure treatment
Study: 6703371
Drug: Naloxone (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (after fentanyl, morphine, or meperidine)
Study: 21045096
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (2 g/d)
Study: 7678871
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg finasteride daily
Study: 10210385
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg finasteride daily in men with prostates larger than 40 cc
Study: 2103193
Drug: 5‐isosorbide mononitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐isosorbide mononitrate (20 mg)
Study: 391626
Drug: 0.025% oxymetazoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% oxymetazoline ophthalmic solution
Study: 23307507
Drug: Standard Colonoscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Colonoscopy (SC) and Colon Capsule Endoscopy (CCE)
Study: 21979997
Drug: Supplementation with
Normalized name: Similac For Supplementation with Iron Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation with meso‐zeaxanthin (10.6 mg), lutein (5.9 mg), and zeaxanthin (1.2 mg)
Study: 17933885
Drug: Occupational health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational health intervention including consultation and possible referral to specialist treatment.
Study: 12092748
Drug: Ciprofloxacin alone
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin alone (20 mg/kg) in Rat Study 1
Study: 12092748
Drug: Ciprofloxacin with
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin with calcium chloride (20 mg/kg) in Rat Study 2
Study: 12092748
Drug: Ciprofloxacin alone
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin alone (400 mg) in Study 1 (volunteer study)
Study: 12092748
Drug: Ciprofloxacin with
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin with calcium polycarbophil (400 mg + 1200 mg) in Study 2 (volunteer study)
Study: 392699
Drug: Fluoride supplement
Normalized name: Fluoride supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride supplement in sugar products (10 mg F as NaF per kg of sugar) and NaHCO3 + KH2PO4 mixture in candies (substituting for 2.5% of sugar).
Study: 392699
Drug: Fluoride supplements
Normalized name: Fluoride supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride supplements in test subjects.
Study: 27664141
Drug: Community therapists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community therapists delivering family therapy as routine standard of care
Study: 25679187
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg as atorvastatin calcium tablets
Study: 23944648
Drug: Intramyocardial injections
Normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial injections of 2000 μg plasmid vascular endothelial growth factor 165
Study: 11157143
Drug: IL‐1Ra 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐1Ra 30 mg/day
Study: 3246167
Drug: Ceftriaxone (CRO:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (CRO: Rocephin) 100 mg/kg/day, once daily
Study: 3246167
Drug: Ampicillin 160
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampicillin 160 mg/kg/day and chloramphenicol (AMCL) 100 mg/kg/day, every 6 h
Study: 29530747
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen (Ofirmev)
Study: 29199345
Drug: 3D printing
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D printing implant template (TDPIT group)
Study: 29199345
Drug: Conventional implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional implant template (CIT group)
Study: 20373906
Drug: Home delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home delivery of medication
Study: 7772359
Drug: saline 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline 5 ml
Study: 31701652
Drug: Triple-drug chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug chemotherapy with lipiodol diameter ratio values between 1 and 3
Study: 31701652
Drug: Lipiodol ≤10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipiodol ≤10 mL
Study: 29151359
Drug: Standard EGFR-TKIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard EGFR-TKIs (gefitinib 250 mg once daily or erlotinib 150 mg once daily)
Study: 24486637
Drug: Sacral neuromodulation
Normalized name: Boswellia sacra whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacral neuromodulation (InterStim) therapy
Study: 22520521
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (MED)
Study: 17977931
Drug: Anodyne monochromatic
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anodyne monochromatic infrared photo energy (MIRE) treatment, used at home every day for 40 min for 90 days.
Study: 17977931
Drug: Sham treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment, used at home every day for 40 min for 90 days.
Study: 16214012
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg/d)
Study: 9781975
Drug: trimetazidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimetazidine (20 mg 3 times daily)
Study: 7876047
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (IVSK) 1.5 million units within 6 hours of onset of chest pain, along with beta-blockers, aspirin, and heparin unless contraindicated.
Study: 7876047
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy without IVSK.
Study: 2465851
Drug: Cocaine and
Normalized name: Cocaine and morphine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine and adrenaline combination
Study: 30919670
Drug: Melatonin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (0.1 to 0.2 mg/kg, PO, q 12 h for 7 days)
Study: 30919670
Drug: Placebo (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (150 mg of lactose powder in a capsule, PO, q 12 h for 7 days)
Study: 28746195
Drug: Facial candling
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Facial candling treatment
Study: 28746195
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment given)
Study: 26079533
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion at a rate of 2 μg/kg/min until 48 h after surgery
Study: 23437535
Drug: Intradermally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermally administered inactivated poliovirus vaccine (0.1 mL) using Biojector 2000
Study: 23437535
Drug: Intramuscularly administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscularly administered inactivated poliovirus vaccine (0.5 mL) using a pre-filled syringe
Study: 7955810
Drug: Fluvoxamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100 to 150 mg daily for 16 days)
Study: 7955810
Drug: Control (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (single oral dose of diazepam 10 mg)
Study: 26003419
Drug: Group cognitive-behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behavioral therapy (CBT) for children
Study: 19919878
Drug: Enoxaparin 20mg
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 20mg twice daily for 14 days, started 24-36 hours after surgery
Study: 18990744
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g GTE per day for 12 months
Study: 8857072
Drug: Moclobemide 200
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 200 mg b.d. for 14 days
Study: 8857072
Drug: Selegiline 5
Normalized name: selegiline 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline 5 mg b.d. for 14 days
Study: 8857072
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with moclobemide and selegiline
Study: 1352497
Drug: Salbutamol (full
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (full agonist)
Study: 6391231
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clindamycin and tobramycin
Study: 30153781
Drug: Protocol-guided strategy
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol-guided strategy using stroke volume variation to guide administration of bolus fluid
Study: 27128738
Drug: SMART principles
Normalized name: Muguettine principle
DrugBank: Hydroxycitronellal (DB14187)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMART principles for goal formulation
Study: 24783923
Drug: Standardized treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized treatment with TCM combined with WM (oral Chinese decoctions three times daily for 4 weeks)
Study: 24783923
Drug: Non-standardized treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-standardized treatment with TCM combined with WM (oral Chinese decoction for promotion of blood circulation for 4 weeks)
Study: 24783923
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (standardized and non-standardized treatment)
Study: 19347843
Drug: Highly active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly active antiretroviral therapy (ART)
Study: 17447222
Drug: Reconcile (fluoxetine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reconcile (fluoxetine, 1 to 2 mg/kg/day) plus behavior management
Study: 14716221
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low-dose nifedipine GITS 20 mg and losartan 50 mg
Study: 9855086
Drug: Intravenous omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous omeprazole infusion (80 mg + 8 mg/h) for 24 hours followed by 8, 4 or 2 mg/h.
Study: 9855086
Drug: Intravenous omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous omeprazole infusion (80 mg + 8 mg/h) for 3 days followed by oral omeprazole 20 mg once daily.
Study: 28263212
Drug: Cabazitaxel (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel (4 cycles of 25 mg/m2 + 2 cycles of 20 mg/m2) combined with 188Re-HEDP (40 MBq/kg)
Study: 28263212
Drug: Cabazitaxel (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel (6 cycles of 25 mg/m2) combined with 188Re-HEDP (40 MBq/kg)
Study: 28263212
Drug: Cabazitaxel monotherapy
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel monotherapy
Study: 21525848
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (SSRIs) administered orally on single days to assess immediate effects on motor function.
Study: 16339819
Drug: Enrasentan (60‐90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrasentan (60‐90 mg/day)
Study: 16339819
Drug: Enalapril (10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10‐20 mg/day)
Study: 14724371
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with lipid-lowering drugs (control group).
Study: 8766460
Drug: Counselling intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Counselling intervention (6 weekly sessions, educational and problem-solving components, conducted in the family home)
Study: 3921583
Drug: Combined enteral-parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined enteral-parenteral nutrition (CN)
Study: 30547287
Drug: MCAF5352A (humanized
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCAF5352A (humanized monoclonal antibody targeting IL-17A and IL-17F)
Study: 23254183
Drug: Daily consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily consumption of F&V by parents
Study: 21574683
Drug: Manual-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual-guided treatment
Study: 21574683
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (nonmanualized treatment)
Study: 18050382
Drug: CF101 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF101 1.0 mg bid for 12 weeks
Study: 18050382
Drug: CF101 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF101 0.1 mg bid for 12 weeks
Study: 18050382
Drug: CF101 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF101 4.0 mg bid for 12 weeks
Study: 18050382
Drug: CF101 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF101 (all doses)
Study: 16681980
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy and radiotherapy concurrently
Study: 29722791
Drug: Intravenous NEPA
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous NEPA (fosnetupitant 235 mg plus PALO 0.25 mg)
Study: 29722791
Drug: Oral NEPA
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral NEPA (netupitant 300 mg plus PALO 0.50 mg)
Study: 29722791
Drug: Intravenous NEPA
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous NEPA
Study: 24005613
Drug: PLD 50
Normalized name: pLDLR-Neo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD 50 mg/m² q28 and vandetanib 100 mg/d po
Study: 12601765
Drug: Commercial subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial subunit vaccine
Study: 12601765
Drug: Commercial split
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial split virion vaccine
Study: 9357387
Drug: Debrisoquin 10
Normalized name: debrisoquin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debrisoquin 10 mg
Study: 9357387
Drug: Mephenytoin 100
Normalized name: mephenytoin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mephenytoin 100 mg
Study: 8387346
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (etoposide, epirubicin, and cis-platinum, days 1-3, every 21 days)
Study: 8387346
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by rhGM‐CSF (10 micrograms/kg/day s.c., days 4-14)